$ICU
SeaStar Medical Holding Corp

2022 Q2 Form 10-Q Financial Statement

#000156459022029552 Filed on August 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $720.0K $460.0K $375.4K
YoY Change 243.31% 43.75%
% of Gross Profit
Research & Development $596.0K $355.0K $500.0K
YoY Change 10.37% -52.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $341.8K $218.7K $375.4K
YoY Change 62.97% 73.59%
Operating Profit -$1.404M -$812.0K
YoY Change 569.35% 544.66%
Interest Expense $1.586M $3.605M $491.0K
YoY Change -189.47% 96.72%
% of Operating Profit
Other Income/Expense, Net $410.0K -$192.0K $0.00
YoY Change 355.56%
Pretax Income $182.6K $3.386M $115.6K
YoY Change -109.21% 98.43%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0% 0.0%
Net Earnings $182.6K $3.386M $115.6K
YoY Change -109.21% 98.43% -2307.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.14
Diluted Earnings Per Share $14.00K $259.6K $8.857K
COMMON SHARES
Basic Shares Outstanding 7.239M 7.239M
Diluted Shares Outstanding 7.239M 7.239M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.02K $88.06K $51.57K
YoY Change -76.74% -82.5%
Cash & Equivalents $79.02K $88.06K $51.57K
Short-Term Investments
Other Short-Term Assets $105.9M $105.9M $301.1K
YoY Change 17212.99% 13842.59%
Inventory
Prepaid Expenses $188.9K $14.82K
Receivables
Other Receivables $58.00K
Total Short-Term Assets $106.0M $106.0M $105.9M
YoY Change 11038.38% 8291.9% 39250.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $105.6M
YoY Change -100.0% -100.0%
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $106.0M $106.0M $105.9M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $106.0M $106.0M $105.9M
YoY Change -0.54% -0.82% 39250.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $670.0K $200.0K $85.00K
YoY Change
Accrued Expenses $1.037M $309.5K $376.7K
YoY Change 2003.46% 7063.66% 206.18%
Deferred Revenue
YoY Change
Short-Term Debt $911.9K $310.0K $0.00
YoY Change
Long-Term Debt Due $2.550M $2.460M
YoY Change
Total Short-Term Liabilities $7.382M $7.571M $10.93M
YoY Change 3738.87% 2508.2% 4281.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $60.00K $10.55M
YoY Change -100.0% -99.39%
Total Long-Term Liabilities $0.00 $0.00 $10.55M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.382M $7.571M $10.93M
Total Long-Term Liabilities $0.00 $0.00 $10.55M
Total Liabilities $7.382M $7.571M $10.93M
YoY Change -37.83% -25.77% 4281.72%
SHAREHOLDERS EQUITY
Retained Earnings -$6.997M -$10.57M
YoY Change -35.91% 201690.87%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.997M -$7.179M -$10.57M
YoY Change
Total Liabilities & Shareholders Equity $106.0M $106.0M $105.9M
YoY Change -0.54% -0.82% 39250.41%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income $182.6K $3.386M $115.6K
YoY Change -109.21% 98.43% -2307.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$611.0K -$273.5K -$797.1K
YoY Change 1464.61% -2.43% 605.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $8.130K
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $8.130K
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 601.9K 310.0K 674.7K
YoY Change -598.21% -99.71% 345.62%
NET CHANGE
Cash From Operating Activities -611.0K -273.5K -797.1K
Cash From Investing Activities 0.000 0.000 8.130K
Cash From Financing Activities 601.9K 310.0K 674.7K
Net Change In Cash -9.040K 36.50K -114.3K
YoY Change -94.47% -92.15% -397.67%
FREE CASH FLOW
Cash From Operating Activities -$611.0K -$273.5K -$797.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 lmao Prepaid Insurance And Other Fees
PrepaidInsuranceAndOtherFees
286237
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14817
CY2022Q2 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
105652034
CY2021Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
105581820
CY2022Q2 us-gaap Assets Current
AssetsCurrent
105954910
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39927
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q2 us-gaap Cash
Cash
79023
CY2021Q4 us-gaap Cash
Cash
51567
CY2022Q2 lmao Prepaid Insurance And Other Fees
PrepaidInsuranceAndOtherFees
34906
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
188947
CY2021Q4 lmao Deferred Underwriting Commissions In Initial Public Offering
DeferredUnderwritingCommissionsInInitialPublicOffering
3622500
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1809900
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
341786
CY2022Q2 us-gaap Assets
Assets
105954910
CY2021Q4 us-gaap Assets
Assets
105934441
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1037428
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
376702
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
911940
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6930740
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6997127
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10565770
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6996858
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10565501
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105954910
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
209718
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-1982698
us-gaap Profit Loss
ProfitLoss
3568643
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10929942
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7381768
us-gaap Investment Income Interest
InvestmentIncomeInterest
1754
CY2022Q2 us-gaap Profit Loss
ProfitLoss
182562
us-gaap Profit Loss
ProfitLoss
-276241
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5120840
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-57680
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
67609
us-gaap Investment Income Interest
InvestmentIncomeInterest
70213
dei Entity Central Index Key
EntityCentralIndexKey
0001831868
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Registrant Name
EntityRegistrantName
LMF ACQUISITION OPPORTUNITIES INC.
CY2021Q4 us-gaap Assets Current
AssetsCurrent
105934441
CY2022Q2 lmao Deferred Underwriting Commissions In Initial Public Offering
DeferredUnderwritingCommissionsInInitialPublicOffering
3622500
CY2022Q2 us-gaap Liabilities
Liabilities
7381768
CY2021Q4 us-gaap Liabilities
Liabilities
10929942
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105934441
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
560442
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
335675
CY2022Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1061968
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1061968
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1403754
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-209718
us-gaap Operating Income Loss
OperatingIncomeLoss
-1622410
us-gaap Operating Income Loss
OperatingIncomeLoss
-335675
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1518707
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1772980
us-gaap Profit Loss
ProfitLoss
3568643
us-gaap Profit Loss
ProfitLoss
-276241
lmao Formation Costs Paid By Related Parties
FormationCostsPaidByRelatedParties
126413
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5120840
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-57680
us-gaap Investment Income Interest
InvestmentIncomeInterest
70213
us-gaap Investment Income Interest
InvestmentIncomeInterest
1754
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-77201
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-216426
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
660725
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-73710
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-884484
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-319372
lmao Payments To Acquire Investment In Trust Account
PaymentsToAcquireInvestmentInTrustAccount
105573716
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105573716
lmao Payments For Insurance Financing
PaymentsForInsuranceFinancing
611027
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5738000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103500000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2432549
lmao Proceeds From Notes And Advances Payable Related Party
ProceedsFromNotesAndAdvancesPayableRelatedParty
941940
lmao Repayment From Notes And Advances Payable Related Party
RepaymentFromNotesAndAdvancesPayableRelatedParty
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
911940
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106194424
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
27456
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
301336
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51567
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38388
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79023
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
339724
lmao Reclassification Of Warrants To Liability
ReclassificationOfWarrantsToLiability
8116680
lmao Deferred Underwriting Commissions In Connection With Initial Public Offering
DeferredUnderwritingCommissionsInConnectionWithInitialPublicOffering
3779353
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19764
CY2021Q1 lmao Units Issued During Period Value New Issues
UnitsIssuedDuringPeriodValueNewIssues
103500000
CY2021Q1 lmao Units Issued During Period Value Reclassified To Commitments Subject To Possible Redemption
UnitsIssuedDuringPeriodValueReclassifiedToCommitmentsSubjectToPossibleRedemption
-105570000
CY2021Q1 lmao Underwriting Fees And Offering Costs
UnderwritingFeesAndOfferingCosts
-6211902
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5738000
CY2021Q1 lmao Warrants Classified As Liabilities
WarrantsClassifiedAsLiabilities
-8116680
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
1706457
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-8934361
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1982698
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-10917059
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10565501
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
3386081
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-7179420
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
182562
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6996858
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
0
CY2020Q4 lmao Principal Amount Borrowed For Expenses Of Ipo
PrincipalAmountBorrowedForExpensesOfIPO
300000
CY2020Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-06-30
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of June 30, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
us-gaap Malpractice Insurance Coverage Floor
MalpracticeInsuranceCoverageFloor
250000
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Warrant Liabilities</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. In accordance with ASC 825-10 “Financial Instruments”, offering costs attributable to the issuance of the derivative warrant liabilities have been allocated based on their relative fair value of total proceeds and are recognized in the statement of operations as incurred.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10,350,000 warrants issued in connection with the IPO (the “Public Warrants”) and the 5,738,000 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised. The fair value of the Public Warrants issued and Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.</p>
CY2022Q2 lmao Offering Costs Total
OfferingCostsTotal
6211902
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3622500
CY2022Q2 us-gaap Other Ownership Interests Offering Costs
OtherOwnershipInterestsOfferingCosts
518402
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
lmao Redemption Of Warrants
RedemptionOfWarrants
18.00
lmao Warrants Expiration
WarrantsExpiration
P5Y
lmao Initial Business Combination Completion Period
InitialBusinessCombinationCompletionPeriod
P18M
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16088000
lmao Redemption Of Warrants Description
RedemptionOfWarrantsDescription
if: (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of its Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”); (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions); and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price
lmao Warrant Agreement Description
WarrantAgreementDescription
In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of common shares, all holders of the warrants would be entitled to receive cash for their warrants (the “tender offer provision”).
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1518707
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5120840
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1772980
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-57680

Files In Submission

Name View Source Status
0001564590-22-029552-index-headers.html Edgar Link pending
0001564590-22-029552-index.html Edgar Link pending
0001564590-22-029552.txt Edgar Link pending
0001564590-22-029552-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lmao-10q_20220630.htm Edgar Link pending
lmao-20220630.xsd Edgar Link pending
lmao-ex106_257.htm Edgar Link pending
lmao-ex311_6.htm Edgar Link pending
lmao-ex312_9.htm Edgar Link pending
lmao-ex321_7.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lmao-20220630_cal.xml Edgar Link unprocessable
lmao-20220630_def.xml Edgar Link unprocessable
lmao-20220630_lab.xml Edgar Link unprocessable
lmao-20220630_pre.xml Edgar Link unprocessable
lmao-10q_20220630_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending